Are you up to date on the key clinical data for available immuno-oncologic agents in advanced endometrial and cervical cancers?
This educational series examines the significance and potential impact of immunotherapy and antibody-drug conjugates in patients with advanced endometrial and cervical cancers. Our global experts discuss key clinical data from first- and second-line treatment, management considerations during immuno-oncologic therapy, and more!
Provided by:
In Partnership with:
First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer
Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer
Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
Employing Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies
Employing Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies
